PHARVARIS N V's ticker is PHVS and the CUSIP is N69605108. A total of 21 filers reported holding PHARVARIS N V in Q2 2022. The put-call ratio across all filers is - and the average weighting 2.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $80,638,915 | -18.6% | 4,289,304 | 0.0% | 34.83% | -0.9% |
Q1 2024 | $99,125,815 | -28.2% | 4,289,304 | -12.8% | 35.16% | +70.0% |
Q4 2023 | $137,992,087 | +55.0% | 4,919,504 | +15.4% | 20.68% | -18.1% |
Q3 2023 | $89,003,705 | +37.8% | 4,264,672 | 0.0% | 25.24% | +8.0% |
Q2 2023 | $64,567,134 | +251.8% | 4,264,672 | +87.2% | 23.37% | +129.7% |
Q1 2023 | $18,353,922 | -29.0% | 2,278,575 | -0.8% | 10.17% | +27.0% |
Q4 2022 | $25,837,988 | +46.7% | 2,296,710 | 0.0% | 8.01% | +96.5% |
Q3 2022 | $17,616,000 | -65.4% | 2,296,710 | -0.2% | 4.08% | -71.9% |
Q2 2022 | $50,862,000 | +21.8% | 2,301,451 | -0.1% | 14.48% | +56.4% |
Q1 2022 | $41,771,000 | +26.0% | 2,303,310 | 0.0% | 9.26% | +55.1% |
Q4 2021 | $33,145,000 | -18.8% | 2,303,310 | 0.0% | 5.97% | +46.8% |
Q3 2021 | $40,838,000 | -4.8% | 2,303,310 | 0.0% | 4.07% | -19.7% |
Q2 2021 | $42,911,000 | -33.4% | 2,303,310 | 0.0% | 5.06% | -17.3% |
Q1 2021 | $64,447,000 | – | 2,303,310 | – | 6.12% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management IV, LLC | 3,246,926 | $71,757,000 | 19.32% |
venBio Partners LLC | 2,301,451 | $50,862,000 | 14.48% |
Bain Capital Life Sciences Investors, LLC | 3,180,601 | $70,291,000 | 8.24% |
5AM Venture Management, LLC | 587,600 | $12,986,000 | 3.21% |
Cormorant Asset Management, LP | 1,145,953 | $25,326,000 | 1.92% |
GENERAL ATLANTIC, L.P. | 2,420,155 | $53,485,000 | 0.70% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 827,540 | $18,289,000 | 0.70% |
Novo Holdings A/S | 519,339 | $11,477,000 | 0.56% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,190,343 | $26,307,000 | 0.54% |
Foresite Capital Management V, LLC | 34,142 | $755,000 | 0.53% |